Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Grotz, Travis E ^a   Jakub, James W ^a   Mansfield, Aaron S ^b   Goldenstein, Rachel ^c   Enninga, Elizabeth Ann L ^c   Nevala, Wendy K ^b   Leontovich, Alexey A ^a   Markovic, Svetomir N ^c  

^a MAYO CLINIC   (United States)

^b Department of Oncology ^*  (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

CD4 T cells; CD8 T cells; immunotherapy; inflammation; lymphocytes; melanoma; sentinel lymph node; Th2 polarization; VEGF

Indexed keywords

CD14 ANTIGEN; CD20 ANTIGEN; CD68 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 12; INTERLEUKIN 13 RECEPTOR; RANTES; STAT4 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MACROPHAGE; MALE; MELANOMA; POLARIZATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENTINEL LYMPH NODE; T CELL DEPLETION; TH2 CELL;

EID: 84940479404     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1026504     Document Type: Article

References (31)

1. C.M.Balch, J.E.Gershenwald, S.J.Soong, J.F.Thompson. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 2011; 104(4):379-85; PMID:21858832; http://dx.doi.org/10.1002/jso.21876
2. D.R.Wen, D.S.Hoon, C.Chang, A.J.Cochran. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989; 30(5):277-82; PMID:2696592; http://dx.doi.org/10.1007/BF01744894
3. D.S.Hoon, R.J.Bowker, A.J.Cochran. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 1987; 47(6):1529-33; PMID:2949828
4. Z.Farzad, W.H.McBride, H.Ogbechi, C.Asnong-Holthoff, D.L.Morton, A.J.Cochran. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma research 1997; 7(Suppl 2):S59-65; PMID:9578418
5. A.S.Mansfield, S.G.Holtan, T.E.Grotz, J.B.Allred, J.W.Jakub, L.A.Erickson, S.N.Markovic. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol 2011; 4:487-94; PMID:21151098; http://dx.doi.org/10.1038/modpathol.2010.227
6. W.K.Nevala, C.M.Vachon, A.A.Leontovich, C.G.Scott, M.A.Thompson, S.N.Markovic. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009; 15(6):1931-9; PMID:19240164; http://dx.doi.org/10.1158/1078-0432.CCR-08-1980
7. F.A.Mahmoud, N.I.Rivera. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4(3):250-5; PMID:11937016; http://dx.doi.org/10.1007/s11912-002-0023-1
8. J.Yuan, J.Zhou, Z.Dong, S.Tandon, D.Kuk, K.S.Panageas, P.Wong, X.Wu, J.Naidoo, D.B.Page et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2(2):127-32; PMID:24778276; http://dx.doi.org/10.1158/2326-6066.CIR-13-0163
9. A.S.Mansfield, W.K.Nevala, E.A.Lieser, A.A.Leontovich, S.N.Markovic. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2(5):e24436; PMID:23762809; http://dx.doi.org/10.4161/onci.24436
10. F.S.Hodi, D.Lawrence, C.Lezcano, X.Wu, J.Zhou, T.Sasada, W.Zeng, A.Giobbie-Hurder, M.B.Atkins, N.Ibrahim et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2(7):632-42; PMID:24838938; http://dx.doi.org/10.1158/2326-6066.CIR-14-0053
11. S.Sebastiani, P.Allavena, C.Albanesi, F.Nasorri, G.Bianchi, C.Traidl, S.Sozzani, G.Girolomoni, A.Cavani. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 2001; 166(2):996-1002; PMID:11145678; http://dx.doi.org/10.4049/jimmunol.166.2.996
12. A.Gonzalez-Martin, L.Gomez, J.Lustgarten, E.Mira, S.Manes. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011; 71(16):5455-66; PMID:21715565; http://dx.doi.org/10.1158/0008-5472.CAN-11-1687
13. P.Ngai, S.McCormick, C.Small, X.Zhang, A.Zganiacz, N.Aoki, Z.Xing. Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect Immun 2007; 75(5):2244-52; PMID:17307945; http://dx.doi.org/10.1128/IAI.00024-07
14. R.J.Critchley-Thorne, N.Yan, S.Nacu, J.Weber, S.P.Holmes, P.P.Lee. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4(5):e176; PMID:17488182; http://dx.doi.org/10.1371/journal.pmed.0040176
15. J.P.Girard, C.Moussion, R.Forster. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nature reviews. Immunology 2012; 12(11):762-73; PMID:23018291
16. R.Hino, K.Kabashima, Y.Kato, H.Yagi, M.Nakamura, T.Honjo, T.Okazaki, Y.Tokura. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116(7):1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
17. J.Dulos, G.J.Carven, S.J.van Boxtel, S.Evers, L.J.Driessen-Engels, W.Hobo, M.A.Gorecka, A.F.de Haan, P.Mulders, C.J.Punt et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35(2):169-78; PMID:22306905; http://dx.doi.org/10.1097/CJI.0b013e318247a4e7
18. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
19. M.Ahmadzadeh, L.A.Johnson, B.Heemskerk, J.R.Wunderlich, M.E.Dudley, D.E.White, S.A.Rosenberg. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114(8):1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792
20. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
21. H.Torisu-Itakura, J.H.Lee, R.P.Scheri, Y.Huynh, X.Ye, R.Essner, D.L.Morton. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res 2007; 13(11):3125-32; PMID:17545514; http://dx.doi.org/10.1158/1078-0432.CCR-06-2645
22. P.Redondo, I.Sanchez-Carpintero, A.Bauza, M.Idoate, T.Solano, M.C.Mihm, Jr. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003; 49(2):255-63; PMID:12894074; http://dx.doi.org/10.1067/S0190-9622(03)00921-6
23. Y.S.Kim, S.J.Choi, Y.M.Tae, B.J.Lee, S.G.Jeon, S.Y.Oh, Y.S.Gho, Z.Zhu, Y.K.Kim. Distinct roles of vascular endothelial growth factor receptor-1- and receptor-2-mediated signaling in T cell priming and Th17 polarization to lipopolysaccharide-containing allergens in the lung. J Immunol 2010; 185(9):5648-55; PMID:20921519; http://dx.doi.org/10.4049/jimmunol.1001713
24. C.G.Lee, H.Link, P.Baluk, R.J.Homer, S.Chapoval, V.Bhandari, M.J.Kang, L.Cohn, Y.K.Kim, D.M.McDonald et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nature medicine 2004; 10(10):1095-103; PMID:15378055; http://dx.doi.org/10.1038/nm1105
25. K.A.Varker, J.E.Biber, C.Kefauver, R.Jensen, A.Lehman, D.Young, H.Wu, G.B.Lesinski, K.Kendra, H.X.Chen et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14(8):2367-76; PMID:17534686; http://dx.doi.org/10.1245/s10434-007-9389-5
26. S.Kruijff, E.Bastiaannet, A.H.Brouwers, W.B.Nagengast, M.J.Speijers, A.J.Suurmeijer, G.A.Hospers, H.J.Hoekstra. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol 2012; 19(2):620-6; PMID:21861214; http://dx.doi.org/10.1245/s10434-011-2027-2
27. S.Biswas, J.Wrigley, C.East, A.Hern, A.Marshall, J.Dunn, P.Lorigan, M.Middleton, P.Corrie. A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update. Ecancermedicalscience 2008; 2:108; PMID:22275984; http://dx.doi.org/10.3332/ecancer.2008.108
28. R.K.Shrimali, Z.Yu, M.R.Theoret, D.Chinnasamy, N.P.Restifo, S.A.Rosenberg. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70(15):6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153
29. M.S.Block, W.K.Nevala, A.A.Leontovich, S.N.Markovic. Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res 2011; 17(7):1776-83; PMID:21349994; http://dx.doi.org/10.1158/1078-0432.CCR-10-2836
30. A.J.Cochran, R.R.Huang, J.Lee, E.Itakura, S.P.Leong, R.Essner. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006; 6(9):659-70; PMID:16932751; http://dx.doi.org/10.1038/nri1919
31. J.W.Jakub, D.S.Reintgen, S.Shivers, S.Pendas. Regional node dissection for melanoma: techniques and indication. Surg Oncol Clin N Am 2007; 16(1):247-61; PMID:17336247; http://dx.doi.org/10.1016/j.soc.2006.10.012